MTMark Toshner

Mark Toshner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark Toshner has a total of 885 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Targeted Therapy Before Balloon Pulmonary Angioplasty

    by Daniel A. Jeffery, Mark Toshner

  • Open Access

    Pulmonary Haemodynamics After Mechanical Therapy With PEA and BPA Predict Survival in Patients With CTEPH ‐ A Prospective Analysis From the National UK CURATE Registry

    by Eilish Turner‐Frick, Hakim Ghani, Paula Appenzeller, Liliana Amaral‐Almeida, Katherine Bunclark, John Cannon, Karen Sheares, Mark Toshner, Dolores Taboada, Choo Ng, et al.

    Chronic thromboembolic pulmonary hypertension (CTEPH) can be treated by mechanical therapy with pulmonary endarterectomy (PEA) or balloon pulmonary angioplasty (BPA). Haemodynamic treatment goal is ill‐defined. We explored post‐procedure mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), and its relationship with 5‐Year survival and exercise capacity Using 6‐min Walk Distance (6MWD). Consecutive PEA and BPA patients from the UK CURATE database, treated between 2007 and 2022 and 2015–2022, respectively, stratified by 3‐month follow‐up mPAP and PVR by right heart catheter (RHC), had 5‐year survival and 6MWD compared, adjusted for age, sex, drug treatment, and comorbidities in the PEA cohort. Those treated by PEA achieving an mPAP ≤ 25 mmHg had significantly better survival than higher mPAP groups (all pairwise comparisons p < 0.001), with no additional survival advantage below mPAP of 25 mmHg. Those with PVR ≤ 300 dyne.s.cm −5 also had better 5‐year survival ( p < 0.001). Continuous PVR modelling showed a 17% decrease in 5‐year survival for every 100 dyne.s.cm −5 increase in post‐operative PVR ( p < 0.001). And these results remained significant after proportional hazard modelling. Those treated by BPA achieving an mPAP ≤ 30 mmHg and PVR ≤ 300 had a significantly better 5‐year survival with no additional survival advantage below these values. Continuous PVR modelling showed a 48% decrease in 5‐year survival for every 100 dyne.s.cm −5 increase in post‐operative PVR ( p = 0.008). In conclusion, post‐procedure haemodynamics predict 5‐year survival after mechanical therapy for CTEPH. Achieving a mPAP ≤ 25 mmHg for PEA and ≤ 30 mmHg for BPA, or a PVR ≤ 300 dyne.s.cm −5 for both, conferred a better prognosis.

  • Open Access

    Sputum and oral microbiota profiles are associated with long COVID severity and phenotype post-hospitalisation: a UK multicentre, prospective cohort study

    by Daniela Alferes de Lima Headley, Hollian Richardson, Chandani Hennayake, Zsofia Eke, Jamie Stobo, Merete B. Long, Olivia C. Leavy, Matthew Richardson, Omer Elneima, Hamish J.C. McAuley, et al.

    Background: Acute COVID-19 alters the airway microbiota. Whether these changes persist post-COVID-19 and contribute to long COVID is unknown. We aimed to describe the microbiota by long COVID severity and subtype, and identify links with inflammation. Methods: Adults were prospectively recruited to the longitudinal UK Post-hospitalisation COVID-19 study (PHOSP-COVID). Patients were grouped by previously described “severity clusters” (of ongoing health impairments) and symptom subgroups. Oral and sputum microbiota (at 6 months post-discharge) were characterised through 16S ribosomal RNA gene amplicon sequencing, and microbiota diversity was assessed. Co-occurrence network analysis identified keystone taxa. Associations between keystone taxa and plasma inflammatory proteins were assessed through Spearman's rank correlations. Results: 771 participants had their microbiota assessed. Of participants with oral rinses and “severity cluster” assignment (mean age 57.5 years), 278 out of 722 (38.5%) were women. The “very severe” cluster, in which disease was predominantly pulmonary in nature, was associated with a distinct microbiota profile post-COVID-19. Reduced lung function was associated with a distinct oral microbiota profile. Persistent neurocognitive symptoms were associated with a distinct oral microbiota profile, while gastrointestinal symptoms were associated with a distinct sputum microbiota profile. Microbiota keystone taxa shifted to a higher prevalence of lactic acid bacteria associated with worse health outcomes. Lactic acid bacteria abundance was associated with elevated blood inflammatory proteins. Conclusion: Distinct oral and sputum microbiota profiles were associated with pulmonary function and with neurocognitive and gastrointestinal symptoms in long COVID. Shifts in keystone microbiota taxa linked with inflammation, based on worse health outcomes, suggest a potential role change for lactic acid bacteria, which may be associated with the host immune response.


  • Open Access

    Defining the preadmission factors that modify risk of acute complications, survival and long-term recovery from COVID-19: prospective, longitudinal, multisite, cohort study based in England

    by H E Baxendale, Martin Law, Claire Matthews, Janet Piggott, Rama Vancheeswaran, Alain Vuylsteke, Catherine Wilson, Erin Hopley, Mark Toshner, Iryna Boubriak, et al.

    Objectives: To understand the pre-admission factors associated with COVID-19 clinical outcome with and without controlling for acute COVID-19 severity score. Design: We ran a prospective, longitudinal, multicentre cohort study. Setting: Patients were recruited from four hospitals and one community General Practice in England Participants: 425 patients with COVID-19 from the start of the UK pandemic in April 2020 through the first three waves with study completing in 2022. Primary and secondary outcome measures: Data were collected and analysed to identify demographic factors and preadmission symptoms for hospitalised patients that were associated with COVID-19 disease severity at recruitment, acute clinical course and long-term recovery. Analysis methods included logistic regression, time-to-event analysis, mixed-effect models and K-medoids clustering. Results: The cohort was skewed to patients with severe COVID (60%). Preadmission symptom cluster was associated with risk of thrombosis (OR 2.7 (95% CI 1.6 to 6.1), p=0.021) and renal disease (OR 3.3 (95% CI 1.4 to 8.0), p=0.008). Duration of symptoms less than 1 week was associated with pneumothorax (OR 3.1 (95% CI 1.2 to 8.3), p=0.025). Renal complications were more likely to be seen in the first wave compared with the second wave of the pandemic (OR 3.4 (95% CI 1.5 to 7.5), p=0.003). Using a logistic regression model, survival to discharge was associated with white (vs unknown) ethnicity (OR 6.6 (95% CI 2.8 to 15.2), p<0.0001), lower age (60 years, OR 4.9 (95% CI 1.2 to 20.0), p=0.027) and absence of comorbidities (OR 2.7 (95% CI 1.2 to 5.9), p=0.016). However, using a survival model, hazard of death was increased for all hospitalised who had duration of symptoms less than 1 week (HR 5.6 (95% CI 1.3 to 24.4), p=0.023) or had comorbidities (HR 33.3 (95% CI 3.1 to 333.3), p=0.0035). Over 80% of patients reported long-term sequelae with neuromuscular and cognitive effects dominating early on and mood disturbance and breathlessness persisting to 12 months. Gender had the strongest association with dyspnoea (OR 99.8 (95% CI 2.4 to 4123.1, p=0.02) and persistent mood disorder (OR 8.3 (95% CI 1.7 to 39.9), p=0.008) and associated with persistent gastrointestinal problems (loose bowels (OR 3.3 (95% CI 1.1 to 10.8), p=0.045), abdominal pain (OR 5.0 (95% CI 1.4 to 18.1), p=0.014), constipation (OR 3.8 (95% CI 1.6 to 9.2), p=0.003)) and cognitive problems (OR 2.3 (95% CI 1.1 to −4.8), p=0.024). Conclusions: These results support an association between specific demographic factors and early infection symptoms that impact on acute and long-term outcomes of COVID-19 in this cohort after accounting for COVID-19 disease severity at enrolment. Understanding the disease mechanisms that explain these relationships is needed to inform targeted therapeutics to prevent and/or manage these complications.

  • Actigraphy in Pulmonary Hypertension Clinical Trials

    by Mark Toshner, Norman Morris

  • Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension

    by Rowena J. Jones, Eckart M. D. D. De Bie, Nina Deliu, Anthony Y. K. C. Ng, Benjamin J. Dunmore, Stefan Gräf, Christophe Guignabert, Marc Humbert, Laurent Savale, Ly Tu, et al.

    Pulmonary arterial hypertension (PAH) is a rare, life-limiting disease where imbalances in the transforming growth factor–β (TGF-β) and bone morphogenetic protein receptor type II (BMPR-II) superfamily pathways have causal roles in hereditary and idiopathic forms of the disease. These pathways are emerging attractive candidates for therapeutic intervention, but there is an unmet need for clinically relevant and practical biomarkers that can measure target engagement, partly because of the inaccessibility of lung tissue in disease for molecular profiling. Here, we explored the surrogate capacity of peripheral blood bone morphogenetic protein (BMP) pathway–specific markers using samples collected in the StratosPHere 1 study using both cell surface assessment of BMPR-II receptor levels and quantitative PCR for the assessment of downstream target engagement. Downstream BMPR-II canonical and noncanonical signaling was measurable and altered in whole blood in both discovery and international replication cohorts, and transcriptomic signatures were clustered by discrete gene modules that associated with clinical outcomes and mortality. We derived a transcriptomic biomarker panel that was repeatable, reproducible, and longitudinally stable for use in early phase, target engagement clinical trials. The biomarker panel was used in a pilot study of nine sotatercept-treated patients with PAH to test the effect of the therapy on the BMP pathway; analysis suggested that sotatercept did not rebalance or increase BMPR-II pathway signaling but rather led to a reduction, possibly due to depletion of circulating BMP9 and BMP10.


  • Open Access

    BMPR-II biomarkers for testing therapeutic efficacy in pulmonary arterial hypertension –the StratosPHere 1 study

    by Rowena J. Jones, Eckart M.D.D. De Bie, Anthony Y.K.C. Ng, Benjamin J. Dunmore, Nina Deliu, Stefan Graf, Allan Lawrie, Joseph Newman, Gary Polwarth, Christopher J. Rhodes, et al.

    Pulmonary arterial hypertension (PAH) is a rare, life-limiting disease where deficiency of the TGF/BMP pathways have causal roles in hereditary and idiopathic forms. It is an attractive candidate for therapeutic intervention but there is an unmet need for clinically-relevant and practical biomarkers that can measure target engagement. A major challenge has been the inaccessibility of lung tissue in disease for molecular profiling. Here we explore the surrogate capacity of peripheral blood BMP pathway-specific markers. We demonstrate that BMPR-II in flow cytometrically characterised white blood cell subsets is reduced in a proportion of patients, however proteomic analysis demonstrates pleiotropic alterations of TGFβ/BMP modulators. Downstream BMPR-II canonical and non-canonical signalling is impacted and measurable in whole blood. We present discovery and international replication cohorts for a transcriptomic BMPR-II signalling signature. The composite biomarker panel is repeatable, reproducible, longitudinally stable and expressed in correlated gene modules in PAH which associate with clinical outcomes. The assay performance characteristics of the biomarker panel make it feasible for early phase, target engagement clinical trials and an adaptive three arm study of two pre- clinically validated modulators of BMPR-II is underway. One Sentence Summary: The first demonstration of clinically-relevant BMP biomarker panels validated in international populations of patients with PAH.

  • Open Access

    GDF15 is a putative biomarker for distinguishing pulmonary veno-occlusive disease and pulmonary arterial hypertension

    by Amit Prabhakar, Eckart M.D.D. De Bie, Jacqueline T. DesJardin, Prajakta Ghatpande, Stefan Gräf, Luke S. Howard, S. John Wort, Colin Church, David G. Kiely, Emily Sumpena, et al.

    Study identifies GDF15 as a biomarker—accurately distinguishing PVOD from other PAH forms and predicting outcomes across PVOD, IPAH, and HPAH—advancing earlier diagnosis and personalized treatment.


  • Open Access

    A cautionary note on the naive use of general-population biobanks to study pulmonary arterial hypertension, with a focus on Mendelian randomisation

    by Benjamin Woolf, Eckart De Bie, Vallerie McLaughlin, Stefan Gräf, Mark Toshner, Martin R. Wilkins, Christopher J. Rhodes, Stephen Burgess

    Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure >20 mmHg [1]. Patients with PH are assigned to one of five internationally recognised groups. Pulmonary arterial hypertension (PAH), or group 1 PH, is a heterogeneous collection of conditions characterised by increased precapillary pulmonary vascular resistance. Groups 2 to 5 PH comprise PH caused, in turn, by left heart disease, lung diseases (e.g. COPD), chronic thromboembolism, and miscellaneous causes such as haematological diseases.